Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US9382233B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9382233-B2 |
| Application number | US-201314408257-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2013 |
| Priority date | Jun 13, 2012 |
| Publication date | Jul 5, 2016 |
| Grant date | Jul 5, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.
Opening claim text (preview).
What is claimed is: 1. A crystalline benzyl alcohol solvate of vilazodone hydrochloride characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta at approximately 9.5, 10.6, 13.5, 15.6, 22.3 and 26.1 or at approximately 10.5, 13.3, 15.8, 19.5, 21.2, and 24.7. 2. The crystalline benzyl alcohol solvate of vilazodone hydrochloride of claim 1 , wherein the crystalline benzyl alcohol solvate of vilazodone hydrochloride is characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta, at approximately 9.5, 10.6, 13.5, 15.6, 22.3, and 26.1, and wherein the molar ratio of vilazodone hydrochloride to benzyl alcohol is approximately 1:0.5. 3. The crystalline benzyl alcohol solvate of vilazodone hydrochloride of claim 1 , wherein the crystalline benzyl alcohol solvate of vilazodone hydrochloride is characterized by a PXRD diffractogram comprising peaks, in terms of degrees 2-theta, at approximately 10.5, 13.3, 15.8, 19.5, 21.2, and 24.7, and wherein the molar ratio of vilazodone hydrochloride to benzyl alcohol is approximately 1:1. 4. The vilazodone hydrochloride benzyl alcohol solvate of claim 2 , wherein the PXRD diffractogram further comprises peaks, in terms of degrees 2-theta, at approximately 5.3, 11.2, 14.6, 17.5, 19.1, 20.5, and 24.5. 5. The vilazodone hydrochloride benzyl alcohol solvate of claim 2 characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in FIG. 1 . 6. The vilazodone hydrochloride benzyl alcohol solvate of claim 2 characterized by a 1% KBr FTIR spectrum comprising peaks, in terms of cm −1 , at approximately 3228, 2216, 1676, 1607, 1579, 1472, 1443, and 1380. 7. The vilazodone hydrochloride benzyl alcohol solvate of claim 6 characterized by a FTIR spectrum substantially similar to the FTIR spectrum as depicted in FIG. 2 . 8. The vilazodone hydrochloride benzyl alcohol solvate of claim 3 , wherein the PXRD diffractogram further comprises peaks, in terms of degrees 2-theta, at approximately 9.2, 18.6, 20.2, 22.3, 23.3, and 25.4. 9. The vilazodone hydrochloride benzyl alcohol solvate of claim 3 characterized by a PXRD diffractogram substantially similar to the PXRD diffractogram as depicted in FIG. 3 . 10. The vilazodone hydrochloride benzyl alcohol solvate of claim 3 characterized by a 1% KBr FTIR spectrum comprising peaks, in terms of cm −1 , at approximately 3237, 2584, 2210, 1678, 1605, 1575, 1367, and 1231.
linked by a chain containing hetero atoms as chain links · CPC title
Antidepressants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.